GleamWall
中文EN

BIOE Bio Essence Corp

Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—

Margins

Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%

Returns

ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x

Leverage & solvency

Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.90M$323,940
Cost of revenue$469,153$106,863
Gross profit$1.43M$217,077
SG&A expense$497,809$676,515
Operating income$900,011-$459,438
Interest expense$2,186$2,153
Pretax income$896,997-$1.56M
Income tax$800$800
Net income$896,197-$1.31M
EBITDA$900,246-$458,527
EPS (basic)—-0.03
EPS (diluted)—-0.03
Weighted avg. shares (diluted)38.01M38.01M
Balance sheet
Cash & equivalents—$1,371
Receivables$23,454$5,124
Current assets$422,377$280,692
Intangibles$97$332
Total assets$422,474$281,024
Current liabilities$2.44M$2.80M
Long-term debt$57,482$56,481
Total debt$57,482$56,481
Total liabilities$2.50M$3.25M
Shareholders' equity-$2.07M-$2.97M
Net debt—$55,110
Shares outstanding38.01M38.01M
Cash flow statement
Operating cash flow$1.57M$623,865
Investing cash flow—-$114
Financing cash flow-$1.57M-$622,494
Depreciation & amortization$235$911

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.